ARRIVENT BIOPHARMA, INC. Increase (Decrease) in Accrued Liabilities
ARRIVENT BIOPHARMA, INC. (AVBP) reported Increase (Decrease) in Accrued Liabilities of $5.31 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccruedLiabilities · last filed 2026-08-12
- ARRIVENT BIOPHARMA, INC. increase (decrease) in accrued liabilities for the quarter ending 2026-06-30 was $9.14M, a 30.07% increase year-over-year.
- ARRIVENT BIOPHARMA, INC. increase (decrease) in accrued liabilities for the quarter ending 2026-03-31 was -$3.83M.
- ARRIVENT BIOPHARMA, INC. increase (decrease) in accrued liabilities for the quarter ending 2025-12-31 was $4.43M, a 49.04% increase year-over-year.
- ARRIVENT BIOPHARMA, INC. increase (decrease) in accrued liabilities for the quarter ending 2025-09-30 was $91.00K, a 95.91% decline year-over-year.
- ARRIVENT BIOPHARMA, INC. increase (decrease) in accrued liabilities for fiscal 2025 was $6.67M, a 4.55% increase from fiscal 2024.
- ARRIVENT BIOPHARMA, INC. increase (decrease) in accrued liabilities for fiscal 2024 was $6.38M, a 309.83% increase from fiscal 2023.
- ARRIVENT BIOPHARMA, INC. increase (decrease) in accrued liabilities for fiscal 2023 was $1.56M.
| Period end | Increase (Decrease) in Accrued Liabilities 3 month | Increase (Decrease) in Accrued Liabilities 6 month | Increase (Decrease) in Accrued Liabilities 9 month | Increase (Decrease) in Accrued Liabilities 12 month |
|---|---|---|---|---|
| 2026-06-30 | $9.14M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-12 | $5.31M 10-Q · filed 2026-08-12 | $9.74M derived: sum of 3 quarters · filed 2026-08-12 | $9.83M derived: sum of 4 quarters · filed 2026-08-12 |
| 2026-03-31 | -$3.83M 10-Q · filed 2026-05-11 | $600.00K derived: sum of 2 quarters · filed 2026-05-11 | $691.00K derived: sum of 3 quarters · filed 2026-05-11 | $7.72M derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-12-31 | $4.43M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | $4.52M derived: sum of 2 quarters · filed 2026-03-05 | $11.55M derived: sum of 3 quarters · filed 2026-08-12 | $6.67M 10-K · filed 2026-03-05 |
| 2025-09-30 | $91.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-10 | $7.12M derived: sum of 2 quarters · filed 2026-08-12 | $2.24M 10-Q · filed 2025-11-10 | $5.21M derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-06-30 | $7.03M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-12 | $2.15M 10-Q · filed 2026-08-12 | $5.12M derived: sum of 3 quarters · filed 2026-08-12 | $7.34M derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-03-31 | -$4.88M 10-Q · filed 2026-05-11 | -$1.91M derived: sum of 2 quarters · filed 2026-05-11 | $317.00K derived: sum of 3 quarters · filed 2026-05-11 | $2.46M derived: sum of 4 quarters · filed 2026-05-11 |
| 2024-12-31 | $2.97M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | $5.20M derived: sum of 2 quarters · filed 2026-03-05 | $7.34M derived: sum of 3 quarters · filed 2026-03-05 | $6.38M 10-K · filed 2026-03-05 |
| 2024-09-30 | $2.23M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-10 | $4.37M derived: sum of 2 quarters · filed 2025-11-10 | $3.41M 10-Q · filed 2025-11-10 | $5.04M derived: sum of 4 quarters · filed 2025-11-10 |
| 2024-06-30 | $2.14M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-11 | $1.18M 10-Q · filed 2025-08-11 | $2.82M derived: sum of 3 quarters · filed 2025-08-11 | $1.59M derived: sum of 4 quarters · filed 2025-08-11 |
| 2024-03-31 | -$963.00K 10-Q · filed 2025-05-12 | $672.00K derived: sum of 2 quarters · filed 2025-05-12 | -$549.00K derived: sum of 3 quarters · filed 2025-05-12 | $2.63M derived: sum of 4 quarters · filed 2025-05-12 |
| 2023-12-31 | $1.64M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-03 | $414.00K derived: sum of 2 quarters · filed 2025-03-03 | $3.59M derived: sum of 3 quarters · filed 2025-03-03 | $1.56M 10-K · filed 2025-03-03 |
| 2023-09-30 | -$1.22M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-14 | $1.96M derived: sum of 2 quarters · filed 2024-11-14 | -$79.00K 10-Q · filed 2024-11-14 | |
| 2023-06-30 | $3.18M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-14 | $1.14M 10-Q · filed 2024-08-14 | ||
| 2023-03-31 | -$2.04M 10-Q · filed 2024-05-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Innoviva, Inc. (INVA) | United States | $1.493B | 4.62 |
| Ultragenyx Pharmaceutical Inc. (RARE) | United States | $1.456B | -5.62 |
| OMEROS CORP (OMER) | United States | $1.456B | 5.50 |
| ANAPTYSBIO, INC (ANAB) | United States | $1.546B | -60.20 |
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| Oric Pharmaceuticals, Inc. (ORIC) | United States | $1.367B | -8.00 |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |
| Rapport Therapeutics, Inc. (RAPP) | United States | $1.623B | -14.56 |
| Kardigan, Inc. (KARD) | United States | $1.346B | |
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |